Getting a Novel Antibiotic to Patients

From pre-clinical toxicokinetics to final dose recommendations, Certara helped Cubist Pharmaceuticals obtain regulatory approval of a new treatment for complicated infections.

At least two million people become infected with treatment-resistant bacteria each year in the US alone. At least 23,000 die as a direct result; many more lose their lives to other conditions complicated by the infections. With antibiotic resistance on the rise and a low rate of approvals for new antibiotics, there is urgent need to make new treatment options available to patients quickly, efficiently, and safely.

Certara experts in model-based drug development worked with Cubist Pharmaceuticals to bring the novel antibacterial agent Zerbaxa™ (ceftolozane/tazobactam) from pre-clinical studies through market approval to treat adults with complicated infections. Certara’s model-based analyses incorporated subject data collected in up to 10 clinical studies to support confident go/no go decisions, to improve understanding of drug exposure in diverse populations, and to anticipate and address regulatory needs for the drug’s expedited review and approval.

Learn More LinkedIn Twitter Facebook Email

Powered by GlobalLink OneLink Software